Alzheimer's disease associated with Down syndrome: a genetic form of dementia

Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. Diagnosis of dementia remains a clinical challenge because of the lack of validated diagnostic criteria in this population, and because symptoms are overshadowed by the intellectual disability associated with Down syndrome. In people with Down syndrome, fluid and imaging biomarkers have shown good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease. Most importantly, there are no treatments to prevent Alzheimer's disease, even though adults with Down syndrome could be an optimal population in whom to conduct Alzheimer's disease prevention trials. Unprecedented research activity in Down syndrome is rapidly changing this bleak scenario that will translate into disease-modifying therapies that could benefit other populations.

Automated summary

Adults with Down syndrome are at high risk of developing early-onset dementia, which is the leading cause of death in this population. Diagnosis of dementia remains a challenge due to lack of validated criteria, and biomarkers have shown good diagnostic performances with similar changes to Alzheimer's disease. Despite the lack of treatments to prevent Alzheimer's, unprecedented research in this area may lead to disease-modifying therapies.